WallStSmart
QTTB

Q32 Bio Inc

NASDAQ: QTTB · HEALTHCARE · BIOTECHNOLOGY

$5.18
+14.85% today

Updated 2026-06-04

Market cap
$218.23M
P/E ratio
4.28
P/S ratio
4.06x
EPS (TTM)
$3.01
Dividend yield
52W range
$1 – $15
Volume
0.8M

Q32 Bio Inc (QTTB) Financial statements

SEC filings — annual and quarterly data.

Profit margin
55.49%
Operating margin
31.45%
ROE
71.78%
ROA
18.80%
Debt/equity
0.29x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2016$-8.05M
2017$-29.99M
2018$5.32M$-55.58M100.00%-1,126.01%-1,044.29%
2019$1.67M$-103.92M100.00%-6,599.22%-6,237.45%
2020$2.70M$-128.69M100.00%-4,820.98%-4,762.92%
2021$33.97M$-95.76M71.91%-282.44%-281.90%
2022$6.65M$-42.81M100.00%-589.76%-643.65%
2023$-6.65M$-53.74M100.00%725.53%808.04%
2024$0.00$-47.73M
2025$53.74M$29.82M99.27%31.45%55.49%

Frequently asked questions

What is Q32 Bio Inc's revenue?

Q32 Bio Inc's trailing twelve-month revenue is $53.74M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is QTTB?

In its most recent fiscal year, QTTB ran a gross margin of 99.27%, an operating margin of 31.45%, and a net margin of 55.49%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does QTTB generate?

QTTB produced $-33.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is QTTB's balance sheet healthy?

QTTB holds $48.30M in cash and equivalents against $3.47M in long-term debt, on $42.01M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.